Related Experiment Video
Updated: May 2, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
The translocator protein as a drug target in Alzheimer's disease
Sook W Chua1, Michael Kassiou, Lars M Ittner
1Dementia Research Unit, School of Medical Sciences, Wallace Wurth Building, University of New South Wales, Sydney, NSW 2052, Australia.
Abstract:
The translocator protein (TSPO) recently emerged as a potential drug target in Alzheimer's disease (AD). This has been fuelled mainly by positron emission topography studies that show the upregulation of TSPO in AD, especially in relation to microgliosis and astrogliosis in amyloid-β and tau pathology. Although data as to the exact role of TSPO in AD is still inconclusive, TSPO appears to be involved in neuroinflammatory processes and AD has been shown to involve substantial inflammation. Therefore, further development and investigation of the pharmacological effect of TSPO ligands in AD pathology are warranted.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Pharmacogenomics: Identification of New Drug Targets
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease ll: Pathophysiology
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Ligand-Gated Ion Channel Receptor: Gating Mechanism

